BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28982366)

  • 1. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes.
    Rodríguez M; Bajo-Santos C; Hessvik NP; Lorenz S; Fromm B; Berge V; Sandvig K; Linē A; Llorente A
    Mol Cancer; 2017 Oct; 16(1):156. PubMed ID: 28982366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs.
    Liu H; Li PW; Yang WQ; Mi H; Pan JL; Huang YC; Hou ZK; Hou QK; Luo Q; Liu FB
    BMC Cancer; 2019 Feb; 19(1):129. PubMed ID: 30736753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic.
    Samsonov R; Shtam T; Burdakov V; Glotov A; Tsyrlina E; Berstein L; Nosov A; Evtushenko V; Filatov M; Malek A
    Prostate; 2016 Jan; 76(1):68-79. PubMed ID: 26417675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
    Ghorbanmehr N; Gharbi S; Korsching E; Tavallaei M; Einollahi B; Mowla SJ
    Prostate; 2019 Jan; 79(1):88-95. PubMed ID: 30194772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary exosomal microRNA profiling in intermediate-risk prostate cancer.
    Kim MY; Shin H; Moon HW; Park YH; Park J; Lee JY
    Sci Rep; 2021 Apr; 11(1):7355. PubMed ID: 33795765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.
    Foj L; Ferrer F; Serra M; Arévalo A; Gavagnach M; Giménez N; Filella X
    Prostate; 2017 May; 77(6):573-583. PubMed ID: 27990656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-Vesicles are a Potential Tool to Monitor Therapeutic Efficacy of Carbon Ion Radiotherapy in Prostate Cancer.
    Yu Q; Li P; Weng M; Wu S; Zhang Y; Chen X; Zhang Q; Shen G; Ding X; Fu S
    J Biomed Nanotechnol; 2018 Jan; 14(1):168-178. PubMed ID: 29463374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.
    Daniel R; Wu Q; Williams V; Clark G; Guruli G; Zehner Z
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28621736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Jin X; Chen Y; Chen H; Fei S; Chen D; Cai X; Liu L; Lin B; Su H; Zhao L; Su M; Pan H; Shen L; Xie D; Xie C
    Clin Cancer Res; 2017 Sep; 23(17):5311-5319. PubMed ID: 28606918
    [No Abstract]   [Full Text] [Related]  

  • 10. Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche.
    Sánchez CA; Andahur EI; Valenzuela R; Castellón EA; Fullá JA; Ramos CG; Triviño JC
    Oncotarget; 2016 Jan; 7(4):3993-4008. PubMed ID: 26675257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased urinary exosomal microRNAs in children with idiopathic nephrotic syndrome.
    Chen T; Wang C; Yu H; Ding M; Zhang C; Lu X; Zhang CY; Zhang C
    EBioMedicine; 2019 Jan; 39():552-561. PubMed ID: 30467011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of urinary exosomal microRNAs in IgA nephropathy.
    Min QH; Chen XM; Zou YQ; Zhang J; Li J; Wang Y; Li SQ; Gao QF; Sun F; Liu J; Xu YM; Lin J; Huang LF; Huang B; Wang XZ
    J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28383146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma exosome microRNAs are indicative of breast cancer.
    Hannafon BN; Trigoso YD; Calloway CL; Zhao YD; Lum DH; Welm AL; Zhao ZJ; Blick KE; Dooley WC; Ding WQ
    Breast Cancer Res; 2016 Sep; 18(1):90. PubMed ID: 27608715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomal microRNA signatures in multiple sclerosis reflect disease status.
    Ebrahimkhani S; Vafaee F; Young PE; Hur SSJ; Hawke S; Devenney E; Beadnall H; Barnett MH; Suter CM; Buckland ME
    Sci Rep; 2017 Oct; 7(1):14293. PubMed ID: 29084979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.
    Ramirez-Garrastacho M; Berge V; Linē A; Llorente A
    Br J Cancer; 2022 Feb; 126(3):492-501. PubMed ID: 34811506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
    Fredsøe J; Rasmussen AKI; Mouritzen P; Borre M; Ørntoft T; Sørensen KD
    Int J Cancer; 2019 Nov; 145(9):2558-2567. PubMed ID: 30903800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.
    Lugli G; Cohen AM; Bennett DA; Shah RC; Fields CJ; Hernandez AG; Smalheiser NR
    PLoS One; 2015; 10(10):e0139233. PubMed ID: 26426747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary biomarkers of prostate cancer.
    Fujita K; Nonomura N
    Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer.
    Lin H; Shi X; Li H; Hui J; Liu R; Chen Z; Lu Y; Tan W
    BMC Cancer; 2021 Dec; 21(1):1293. PubMed ID: 34861847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.